The drug, Epidiolex, is intended to help treat seizures stemming from two rare but severe forms of epilepsy that first take hold during childhood.
The drug is produced by GW Pharmaceuticals, a British biotech company that is perhaps best known for the cannabis-based multiple sclerosis drug Sativex. That drug has been approved for use in as many as 30 countries outside of the United States.
The first-of-its-kind approval in the US could lead to more research and development of marijuana-based drugs going forward.
“This approval serves as a reminder that advancing sound development programmes that properly evaluate active ingredients contained in marijuana can lead to important medical therapies,” Scott Gottlieb, the commissioner of the FDA, said in a statement.
While medical marijuana has been legalized for medical purposes in nearly half of the states in the US — and a handful of states have legalized recreational use — the drug is still a Schedule 1 drug under federal law.
To Read The Rest Of This Article By Clark Mindock on Independent
Published: June 25, 2018
Founder & Interim Editor of L.A. Cannabis News